David A. Siegel Heron Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 113,500 shares of HRTX stock, worth $227,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
113,500
Previous 42,100
169.6%
Holding current value
$227,000
Previous $116,000
242.24%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding HRTX
# of Institutions
198Shares Held
129MCall Options Held
94.7KPut Options Held
148K-
Rubric Capital Management LP New York, NY26.7MShares$53.4 Million2.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.62MShares$17.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.33MShares$16.7 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA7.6MShares$15.2 Million0.05% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$14 Million58.47% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $238M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...